2-YEAR RESULTS OF TREATMENT WITH METHIONYL HUMAN GROWTH-HORMONE IN CHILDREN WITH TURNER SYNDROME

被引：11

作者：

RONGENWESTERLAKEN, C

FOKKER, MH

WIT, JM

KEIZERSCHRAMA, SMPFD

OTTEN, BJ

OOSTDIJK, W

DELEMARREVANDERWAAL, HA

GONS, MH

BOT, A

机构：

[1] STATE UNIV UTRECHT, DEPT PAEDIAT, UTRECHT, NETHERLANDS

[2] UNIV ROTTERDAM, DEPT PAEDIAT, ROTTERDAM, NETHERLANDS

[3] CATHOLIC UNIV NIJMEGEN, DEPT PAEDIAT, NIJMEGEN, NETHERLANDS

[4] UNIV LEIDEN, DEPT PAEDIAT, LEIDEN, NETHERLANDS

[5] FREE UNIV AMSTERDAM, DEPT PAEDIAT, 1007 MC AMSTERDAM, NETHERLANDS

[6] UNIV AMSTERDAM, DEPT PAEDIAT, AMSTERDAM, NETHERLANDS

[7] ERASMUS UNIV, DEPT ENDOCRINOL GROWTH & REPROD, 3000 DR ROTTERDAM, NETHERLANDS

来源：

ACTA PAEDIATRICA SCANDINAVICA | 1990年 / 79卷 / 6-7期

关键词：

growth; growth hormone; Turner syndrome;

D O I：

10.1111/j.1651-2227.1990.tb11531.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Methionyl growth hormone (somatrem) in a daily dosage of 4 IU/m2 body surface area was administered to 16 girls with Turner syndrome. Low dose ethinyl estradiol (0.1 μg/kg weight) was added in girls aged 13 years or more. Mean (SD) height velocity increased from 3.4 (0.9) to 7.2 (1.7) and 5.3 (1.3) cm/year in the first and second year, respectively. Bone age advanced 1.8 years over 2 years and predicted adult height was increased. Apart from the occurrence of anti-GH antibodies there were no side effects. In conclusion, somatrem is an efficacious and safe therapy for short stature in Turner syndrome over a period of 2 years. Longer follow-up is needed before conclucions about its effect on final height can be drawn.

引用

页码：658 / 663

页数：6

共 26 条

[1]

[Anonymous], 1959, RADIOGRAPH ATLAS SKE

[2] LI HUMAN GROWTH HORMONE ADMINISTRATION IN GONASAL DYSGENESIS [J].